CliffBio
small molecule

MOVIPREP

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

Loss of exclusivity—loss of exclusivity
CompanySalix Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameMOVIPREP
Active ingredientASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE
Strength4.7GM;100GM;1.015GM;5.9GM;2.691GM;7.5GM
Dosage formFOR SOLUTION
RouteORAL
ModalitySmall molecule
FDA approvalAugust 2006
Marketing statusRX

More from Salix Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.